December 18, 2013
Minimus Spine Inc. announced it has secured $1.75 million in funding from the State of Texas’ Emerging Technology Fund.
According to a press release, the two-tranche convertible debt investment will support commercialization of its TriJection syringe cartridge intended as a non-surgical treatment for lumbar disc herniation.
“We are pleased to have the state of Texas as an investor in our company and vision,” David Hooper, PhD, founder and chief executive officer of Minimus Spine, stated in a company release. “This funding will enable us to build upon the successes we have had this year, support our first clinical work in Europe and pave the way for future growth. Austin has a strong entrepreneurial culture and is home to a number of successful spine companies. There is a great deal of local talent. We look forward to growing the business in Austin, but most importantly, improving the lives of patients with our innovative approach to ozone as a therapeutic modality.”
Minimus Spine Website and Literature: http://minimusspine.com/